SGHT Sight Sciences
Sight Sciences earnings company data as of 6:59 AM ET 10/23
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by SGHT's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $185K bought by 1 insider
- None no sales outside a trading plan
- $388K sold by 1 insider under 10b5-1 plans
-
Staffan Encrantz DirectorBuy$69K 14,100 shares at $4.88 +1% to stakeTraded Jun 10 Filed Jun 11
-
Staffan Encrantz DirectorBuy$116K 13,958 shares at $8.31 +1% to stakeTraded Dec 16, 2025 Filed Dec 18, 2025
-
Jeremy B. Hayden Chief Legal OfficerPlanned sale$362K 44,850 shares at $8.08 15% of stakeTraded Nov 25, 2025 Filed Nov 26, 2025
-
Jeremy B. Hayden Chief Legal OfficerPlanned sale$25K 3,150 shares at $8.01 1.2% of stakeTraded Nov 12, 2025 Filed Nov 14, 2025
Also filed in the last 12 months, not counted as buying or selling: 36 sales to cover taxes, 14 stock grants, and 6 option exercises.
SEC filings
Recent issuer filings from EDGAR, 13 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 5.02 | Filing Doc | |
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.07 | Filing Doc | |
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 7.01,9.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| 10-K | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.